skip to main content

Heart Failure with reduced Ejection Fraction (HFrEF) and Type 2 Diabetes — EECC MCQ

Instant feedback + full explanation. One question, done properly.

ModerateHeart FailureHeart Failure with reduced Ejection Fraction (HFrEF) and Type 2 DiabetesEECC

A 57-year-old with type 2 diabetes and symptomatic HFrEF (EF 35%) is not on SGLT2 therapy. According to HF and diabetes guidance, adding which agent reduces HF hospitalization and CV events?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — SGLT2 inhibitor

HF (2022) and ADA (2025) guidance support SGLT2 inhibitors across EF ranges (strong evidence in HFrEF) to reduce HF hospitalizations and CV outcomes. A: DPP-4 inhibitors lack HF benefits; some increase HF hospitalizations. C: GLP-1 RAs reduce ASCVD events but HF benefit less direct. D: TZDs worsen edema/HF. E: Glycemic control only.

Reference: HF (2022) and ADA (2025) guidance support SGLT2 inhibitors across EF ranges (strong evidence in HFrEF) to reduce HF hospitalizations and CV outcomes.